Chimeric Antigen Receptors and Cancer Immunotherapy


Chimeric Antigen Receptors and Cancer Immunotherapy

Davis Auditorium
Walter and Eliza Hall Institute of Medical Research


1g Royal Parade

Booking not required

Further Details

T: (03) 9345 2555

Understanding the molecular signals driving T cell activation is now paramount, as the field moves to using genetically engineered T cells as immunotherapy for cancer. Chimeric antigen receptor (CAR) T cells have emerged as one of the most successful advances in the treatment of cancer. A major challenge for T cell biology is to identify the molecular circuits within this transduction network which produce distinct functional outcomes, including the generation of activated ‘effector’ killer T cells, cytokine producing and memory T cells

In this talk Dr Jenkins will outline how we can hijack immune cells as a treatment for cancer, and combine cross-disciplinary research such as live cell imaging, cell biology and proteomics to discover new treatments for cancer.

No registration is required.

All Seminar/Forums